Monitoring CAR‑BCMA immune cells in multiple myeloma
Official title: CAR-T Immunomonitoring in Multiple Myeloma
Run by Poitiers University Hospital · NCT07342179 · Data updated 2026-11-12
This project will test whether tracking CAR‑BCMA cells and related immune markers in blood and bone marrow can help predict which multiple myeloma patients respond to CAR‑T therapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Poitiers University Hospital Academic / other |
| Drugs / interventions | CAR-T, CAR T, chimeric antigen receptor, CART |
| Locations | 1 site (Poitiers) |
| Status | Recruiting |
| Started | February 13, 2026 |
| Main results expected | October 3, 2032 |
| Study ends | October 3, 2032 |
| Registry record updated | February 18, 2026 |
| Trial ID | NCT07342179 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with a diagnosis of multiple myeloma who are scheduled to receive CAR‑T cell therapy in accordance with French authorizations and who can attend Poitiers for extra blood and bone marrow sampling are ideal candidates.
✕Probably not a fit
Patients who are not receiving CAR‑T therapy, who cannot comply with repeated sampling, or who are in excluded vulnerable groups (for example pregnant individuals or those under legal guardianship) are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will collect clinical data from diagnosis, relapses, prior treatments, and details around CAR‑T therapy, and will take additional blood and bone marrow samples before and up to one year after CAR‑T infusion. Samples will be sent to centralized laboratories to measure CAR‑BCMA cell persistence and the expression of surface proteins CD95 and CD95L as well as soluble CD95L in serum. The project is conducted in collaboration with the IRMETIST INSERM unit at the University of Poitiers and aims to identify cellular immunological markers that correlate with effective responses to CAR‑T treatment. Results will be used to inform patient follow‑up and may guide future personalized immunotherapy approaches.
Why it matters
Potential benefit: If successful, this could help doctors predict who is most likely to benefit from CAR‑T therapy and tailor follow‑up or additional treatments accordingly.
How similar studies have gone: Previous work has shown that long‑term persistence of CAR‑T cells often correlates with better outcomes, but using CD95/CD95L profiling as predictive markers is a more novel approach with limited prior validation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 18 and over * Patient with Multiple Myeloma according to international recommendations, * Patient about to receive CAR-T cell therapy in accordance with the rules and authorizations in France. Exclusion Criteria: * Patients with severely impaired physical and/or psychological health, which, according to the investigator, may affect the participant's compliance with the study. * Simultaneous participation in another study with an ongoing exclusion period. * Individuals receiving enhanced protection, namely minors, pregnant and/or breastfeeding women, individuals deprived of their liberty by a judicial or administrative decision, individuals residing in a healthcare or social care facility, adults under legal guardianship, and finally, patients in emergency situations
Where it's running
-
Chu de Poitiers
Poitiers, France Recruiting
Study contacts
- Study coordinator: Arthur Bobin
- Email: arthur.bobin@chu-poitiers.fr
- Phone: 0033549444201
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma
This early-phase trial tests a one-time in vivo CAR T-cell therapy (SL1617) for people with relapsed or refractory B-cell lymphoma to see if it is safe and tolerable.
-
Cognitive changes after BCMA CAR-T in multiple myeloma
This study tests whether cognitive function changes over time in adults with relapsed or refractory multiple myeloma who receive BCMA CAR-T therapy.
-
CART123 Cells With or Without Ruxolitinib for Relapsed/Refractory AML
This trial tests CART123 cells alone or with ruxolitinib to see if they help kids and young adults with relapsed or treatment‑resistant AML.
-
Autologous CD45 base-edited stem cells plus CART-45 cells for relapsed or refractory hematologic cancers
This phase 1 study tests whether a patient’s own edited stem cells and CART-45 cells can be given safely to treat relapsed or refractory B-cell and T-cell lymphomas and Hodgkin lymphoma.
-
Metabolically armed BCMA CAR-T (Meta10-BCMA) for relapsed or refractory plasma cell neoplasms
This treatment tries a metabolically modified BCMA-targeted CAR-T cell therapy for adults with relapsed or refractory multiple myeloma, plasma cell leukemia, or AL amyloidosis who have had at least three prior therapies.
-
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tries CD5 CAR T-cell therapy, using either the patient's own cells or donor cells, and may bridge to stem-cell transplant for people 14–70 with relapsed or refractory T-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.